| 51 |
22709873 | Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell lines. | 2012 Jun 18 |
2 |
| 52 |
22848366 | Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer. | 2012 |
2 |
| 53 |
21252284 | Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells. | 2011 Mar |
1 |
| 54 |
21385943 | Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. | 2011 Mar 22 |
4 |
| 55 |
21840482 | Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. | 2011 Aug 16 |
2 |
| 56 |
20501798 | Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. | 2010 Jun |
1 |
| 57 |
19060928 | Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. | 2009 Feb 12 |
1 |
| 58 |
18212337 | Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. | 2008 Mar 1 |
1 |
| 59 |
15755991 | Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. | 2005 Mar 1 |
3 |